Spherix Global Insights

September 01, 2022

Spherix Analyzes Reviews of gMG Therapies, Vyvgart, Ultomiris

Neurologists find both Vyvgart (efgartigimod) and Ultomiris (ravulizumab-cwvz) effective for treating generalized myasthenia gravis (gMG), but believe Ultomiris has a more convenient dosing schedule while Vyvgart may have a better safety profile.

That’s according to a recent analysis by the market intelligence firm Spherix Global Insights. Spherix’s analysis of the two treatments was part of Launch Dynamix, a service that provides monthly benchmarks of new products during the first 18 months that they’re commercially available…